Immuno-checkpoint inhibitors in metastatic esophago-gastric cancer
- PMID: 30997225
- PMCID: PMC6424743
- DOI: 10.21037/jtd.2018.12.71
Immuno-checkpoint inhibitors in metastatic esophago-gastric cancer
Conflict of interest statement
Conflicts of Interest: The authors have no conflicts of interest to declare.
Comment on
-
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.J Clin Oncol. 2018 Oct 1;36(28):2836-2844. doi: 10.1200/JCO.2017.76.6212. Epub 2018 Aug 15. J Clin Oncol. 2018. PMID: 30110194 Free PMC article. Clinical Trial.
References
-
- Huang PM, Chen CN. Therapeutic strategies for esophagogastric junction cancer. Formosan Journal of Surgery 2015;48:185-97. 10.1016/j.fjs.2015.08.003 - DOI
Publication types
LinkOut - more resources
Full Text Sources